Reference
1. Schwabe S. Oxcarbazepine: clinical development program.Epilepsia . 1994;35 Suppl 5:S51-3.
doi:10.1111/j.1528-1157.1994.tb05968.x
2. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the
management of epilepsy. CNS Drugs . 2001;15(2):137-63.
doi:10.2165/00023210-200115020-00005
3. Schachter SC. Oxcarbazepine: current status and clinical
applications. Expert Opin Investig Drugs . Jul 1999;8(7):1103-12.
doi:10.1517/13543784.8.7.1103
4. Maiti R, Mishra BR, Sanyal S, Mohapatra D, Parida S, Mishra A. Effect
of carbamazepine and oxcarbazepine on serum neuron-specific enolase in
focal seizures: A randomized controlled trial. Epilepsy Res . Dec
2017;138:5-10. doi:10.1016/j.eplepsyres.2017.10.003
5. Schütz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T. The
metabolism of 14C-oxcarbazepine in man. Xenobiotica . Aug
1986;16(8):769-78. doi:10.3109/00498258609043567
6. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of
oxcarbazepine. Clin Pharmacokinet . 2003;42(12):1023-42.
doi:10.2165/00003088-200342120-00002
7. Di Girolamo G, Opezzo JA, Schere D, Gonzalez CD, Moncalvo JJ. Parent
drug and/or metabolite? Which of them is most appropriate to establish
bioequivalence of two oral oxcarbazepine formulations in healthy
volunteers? Expert Opin Pharmacother . Jul 2007;8(10):1415-23.
doi:10.1517/14656566.8.10.1415
8. Lu Y, Fang Y, Wu X, Ma C, Wang Y, Xu L. Effects of UGT1A9 genetic
polymorphisms on monohydroxylated derivative of oxcarbazepine
concentrations and oxcarbazepine monotherapeutic efficacy in Chinese
patients with epilepsy. Eur J Clin Pharmacol . Mar
2017;73(3):307-315. doi:10.1007/s00228-016-2157-3
9. van Heiningen PN, Eve MD, Oosterhuis B, et al. The influence of age
on the pharmacokinetics of the antiepileptic agent oxcarbazepine.Clin Pharmacol Ther . Oct 1991;50(4):410-9.
doi:10.1038/clpt.1991.158
10. Patsalos PN, Elyas AA, Zakrzewska JM. Protein binding of
oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine,
in patients with trigeminal neuralgia. Eur J Clin Pharmacol .
1990;39(4):413-5. doi:10.1007/bf00315422
11. Flesch G. Overview of the clinical pharmacokinetics of
oxcarbazepine. Clin Drug Investig . 2004;24(4):185-203.
doi:10.2165/00044011-200424040-00001
12. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal
impairment on the pharmacokinetics of oxcarbazepine and its metabolites.Eur J Clin Pharmacol . 1994;47(2):161-7. doi:10.1007/bf00194967
13. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal)
as monotherapy in patients with partial seizures. Neurology . Sep
11 2001;57(5):864-71. doi:10.1212/wnl.57.5.864
14. Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug
monitoring? A critical review. Clin Pharmacokinet .
2008;47(12):767-78. doi:10.2165/0003088-200847120-00002
15. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual
pharmacokinetics for computer-aided drug dosage. Comput Biomed
Res . Oct 1972;5(5):411-59. doi:10.1016/0010-4809(72)90051-1
16. Sasaki T, Tabuchi H, Higuchi S, Ieiri I. Warfarin-dosing algorithm
based on a population pharmacokinetic/pharmacodynamic model combined
with Bayesian forecasting. Pharmacogenomics . Aug
2009;10(8):1257-66. doi:10.2217/pgs.09.65
17. Kanji S, Hayes M, Ling A, et al. Reporting Guidelines for Clinical
Pharmacokinetic Studies: The ClinPK Statement. Clin
Pharmacokinet . Jul 2015;54(7):783-95. doi:10.1007/s40262-015-0236-8
18. Jamsen KM, McLeay SC, Barras MA, Green B. Reporting a population
pharmacokinetic-pharmacodynamic study: a journal’s perspective.Clin Pharmacokinet . Feb 2014;53(2):111-22.
doi:10.1007/s40262-013-0114-1
19. Burns DR, Elswick RK, Jr. Equivalence testing with dental clinical
trials. J Dent Res . Jun 2001;80(6):1513-7.
doi:10.1177/00220345010800060701
20. Ahmad A, Garnett WR. Carbamazepine extended-release capsules vs.
oxcarbazepine: computer simulations of the effect of missed doses on
drug plasma concentrations. Curr Med Res Opin . Sep
2005;21(9):1363-8. doi:10.1185/030079905x59120
21. Ling J, Qian LX, Ding JJ, Jiao Z. [Effects of multiple-trough
sampling design and algorithm on the estimation of population and
individual pharmacokinetic parameters]. Yao Xue Xue Bao . May
2014;49(5):686-94.
22. Liu M, Ma CL, Jiao Z, Gao YC, Liu YX, Wu XY. Population
pharmacokinetics of oxcarbazepine in Chinese epilepsy patients. Article.Yaoxue Xuebao . 2018;53(8):1318-1323.
doi:10.16438/J.0513-4870.2018-0187
23. Sallas WM, Milosavljev S, D’Souza J, Hossain M. Pharmacokinetic drug
interactions in children taking oxcarbazepine. Clin Pharmacol
Ther . Aug 2003;74(2):138-49. doi:10.1016/s0009-9236(03)00124-3
24. Sugiyama I, Bouillon T, Yamaguchi M, Suzuki H, Hirota T, Fink M.
Population pharmacokinetic analysis for 10-monohydroxy derivative of
oxcarbazepine in pediatric epileptic patients shows no difference
between Japanese and other ethnicities. Drug Metab Pharmacokinet .
Apr 2015;30(2):160-7. doi:10.1016/j.dmpk.2014.12.002
25. Northam RS, Hernandez AW, Litzinger MJ, et al. Oxcarbazepine in
infants and young children with partial seizures. Pediatr Neurol .
Nov 2005;33(5):337-44. doi:10.1016/j.pediatrneurol.2005.05.011
26. Park KJ, Kim JR, Joo EY, et al. Drug interaction and pharmacokinetic
modeling of oxcarbazepine in korean patients with epilepsy. Clin
Neuropharmacol . Jan-Feb 2012;35(1):40-4.
doi:10.1097/WNF.0b013e31824150a5
27. Peng J, Zhang HN, Liu ZS, Xu H, Wang Y. Population pharmacokinetics
of oxcarbazepine active metabolite in Chinese children with epilepsy.Int J Clin Pharmacol Ther . Aug 2014;52(8):684-92.
doi:10.5414/cp202078
28. Wang Y, Zhang HN, Niu CH, et al. Population pharmacokinetics
modeling of oxcarbazepine to characterize drug interactions in Chinese
children with epilepsy. Acta Pharmacol Sin . Oct
2014;35(10):1342-50. doi:10.1038/aps.2014.76
29. Lin WW, Wang CL, Jiao Z, et al. Glomerular Filtration Rate Is a
Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult
Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.Ther Drug Monit . Oct 2019;41(5):665-673.
doi:10.1097/ftd.0000000000000644
30. Lin WW, Li XW, Jiao Z, et al. Population pharmacokinetics of
oxcarbazepine active metabolite in Chinese paediatric epilepsy patients
and its application in individualised dosage regimens. Eur J Clin
Pharmacol . Mar 2019;75(3):381-392. doi:10.1007/s00228-018-2600-8
31. Chen CY, Zhou Y, Cui YM, Yang T, Zhao X, Wu Y. Population
pharmacokinetics and dose simulation of oxcarbazepine in Chinese
paediatric patients with epilepsy. J Clin Pharm Ther . Apr
2019;44(2):300-311. doi:10.1111/jcpt.12792
32. Rodrigues C, Chiron C, Rey E, et al. Population pharmacokinetics of
oxcarbazepine and its monohydroxy derivative in epileptic children.Br J Clin Pharmacol . Dec 2017;83(12):2695-2708.
doi:10.1111/bcp.13392
33. Yu Y, Zhang Q, Xu W, Lv C, Hao G. Population pharmacokinetic
modeling of oxcarbazepine active metabolite in Chinese patients with
epilepsy. Eur J Drug Metab Pharmacokinet . Aug 2016;41(4):345-51.
doi:10.1007/s13318-015-0266-5
34. Antunes NJ, van Dijkman SC, Lanchote VL, et al. Population
pharmacokinetics of oxcarbazepine and its metabolite
10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci . Nov
15 2017;109s:S116-s123. doi:10.1016/j.ejps.2017.05.034
35. Wegner I, Edelbroek P, de Haan GJ, Lindhout D, Sander JW. Drug
monitoring of lamotrigine and oxcarbazepine combination during
pregnancy. Epilepsia . Dec 2010;51(12):2500-2.
doi:10.1111/j.1528-1167.2010.02771.x
36. Comets E, Brendel K, Mentré F. Computing normalised prediction
distribution errors to evaluate nonlinear mixed-effect models: the npde
add-on package for R. Comput Methods Programs Biomed . May
2008;90(2):154-66. doi:10.1016/j.cmpb.2007.12.002
37. Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose
and clearance in therapeutic drug monitoring settings: possible
misinterpretation in population pharmacokinetic analyses. J
Pharmacokinet Pharmacodyn . Dec 2005;32(5-6):703-18.
doi:10.1007/s10928-005-0083-6
38. Perucca E. Pharmacokinetic variability of new antiepileptic drugs at
different ages. Ther Drug Monit . Dec 2005;27(6):714-7.
doi:10.1097/01.ftd.0000179847.37965.4e
39. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic
drugs at the extremes of age. Clin Pharmacokinet .
2006;45(4):351-63. doi:10.2165/00003088-200645040-00002
40. Choonara IA, McKay P, Hain R, Rane A. Morphine metabolism in
children. Br J Clin Pharmacol . Nov 1989;28(5):599-604.
doi:10.1111/j.1365-2125.1989.tb03548.x
41. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation
in humans. Pharmacogenetic and developmental aspects. Clin
Pharmacokinet . Jun 1999;36(6):439-52.
doi:10.2165/00003088-199936060-00005
42. Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive
therapy in infants and young children with partial seizures.Neurology . Nov 8 2005;65(9):1370-5.
doi:10.1212/01.wnl.0000186800.18456.72
43. McKee PJ, Blacklaw J, Forrest G, et al. A double-blind,
placebo-controlled interaction study between oxcarbazepine and
carbamazepine, sodium valproate and phenytoin in epileptic patients.Br J Clin Pharmacol . Jan 1994;37(1):27-32.
doi:10.1111/j.1365-2125.1994.tb04234.x
44. French JA, Baroldi P, Brittain ST, Johnson JK. Efficacy and safety
of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy
in patients with refractory partial-onset seizures: a randomized
controlled trial. Acta Neurol Scand . Mar 2014;129(3):143-53.
doi:10.1111/ane.12207
45. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic
drugs–best practice guidelines for therapeutic drug monitoring: a
position paper by the subcommission on therapeutic drug monitoring, ILAE
Commission on Therapeutic Strategies. Epilepsia . Jul
2008;49(7):1239-76. doi:10.1111/j.1528-1167.2008.01561.x